SCHEMBL1035697

SCHEMBL1035697

O=C(O)Cc1c(Cl)cccc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.74
TSHR P16473 2/20 0.57
ALDH1A1 P00352 3/20 0.55
PBRM1 Q86U86 1/20 0.44
KMT2A Q03164 5/20 0.43
ADRA1A P35348 3/20 0.43
MEN1 O00255 3/20 0.43
ADRA2A P08913 3/20 0.43
LMNA P02545 2/20 0.43
CYP3A4 P08684 2/20 0.43
HTR1A P08908 2/20 0.43
CYP2C9 P11712 2/20 0.43
HTR2A P28223 2/20 0.43
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP2D6 P10635 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL109215 0.86 AKR1B1 (1.00) AKR1B1TSHRKMT2AADRA1AMEN1
SCHEMBL5060389 0.86 AKR1B1 (0.56) AKR1B1TSHRALDH1A1HSD17B10ALOX15
Hydrochloric Acid SCHEMBL1374156 0.84 AKR1B1 (0.95) AKR1B1KMT2AADRA1AMEN1ADRA2A
SCHEMBL9364446 0.84 AKR1B1 (0.95) AKR1B1TSHRKMT2AADRA1AMEN1
SCHEMBL8482166 0.82 TSHR (0.59) AKR1B1TSHRALDH1A1PBRM1KMT2A
SCHEMBL8482161 0.82 TSHR (0.59) AKR1B1TSHRALDH1A1PBRM1KMT2A
SCHEMBL30360660 0.82 TSHR (0.59) AKR1B1TSHRALDH1A1PBRM1KMT2A
SCHEMBL3821377 0.81 TSHR (0.57) AKR1B1TSHRALDH1A1PBRM1KMT2A
SCHEMBL9317962 0.81 TSHR (0.57) AKR1B1TSHRALDH1A1PBRM1KMT2A
SCHEMBL7645921 0.80 TSHR (0.52) AKR1B1TSHRALDH1A1PBRM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572660-B1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X CEPTOR THERAPEUTICS INC (US) 2011-01-26 EP disclosed
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents EXELIXIS, INC. (US) 2008-06-05 US disclosed
US-7265131-B2 Isoquinolinone derivatives and their use as therapeutic agents EXELIXIS, INC. (US) 2007-09-04 US disclosed
EP-1572660-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-Ceptor Therapeutics, Inc. (US) 2005-09-14 EP disclosed
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents X-CEPTOR THERAPEUTICS INC. 2004-10-14 US disclosed
WO-2004058717-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-CEPTOR THERAPEUTICS, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents NR1H2, NR1H3, NR1I2 AKR1B1 241/4885TSHR 304/4885ALDH1A1 601/4885
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents NR1H2, NR1I2, NR1H3 AKR1B1 444/4885TSHR 615/4885ALDH1A1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.